KR20250025043A - 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법 - Google Patents
5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법 Download PDFInfo
- Publication number
- KR20250025043A KR20250025043A KR1020257004583A KR20257004583A KR20250025043A KR 20250025043 A KR20250025043 A KR 20250025043A KR 1020257004583 A KR1020257004583 A KR 1020257004583A KR 20257004583 A KR20257004583 A KR 20257004583A KR 20250025043 A KR20250025043 A KR 20250025043A
- Authority
- KR
- South Korea
- Prior art keywords
- htp
- carbidopa
- dose
- low
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623073P | 2018-01-29 | 2018-01-29 | |
| US62/623,073 | 2018-01-29 | ||
| US201862743816P | 2018-10-10 | 2018-10-10 | |
| US62/743,816 | 2018-10-10 | ||
| PCT/US2019/015391 WO2019148087A1 (en) | 2018-01-29 | 2019-01-28 | Compositions and methods of enhancing 5-hydroxytryptophan bioavailability |
| KR1020207024221A KR20200116110A (ko) | 2018-01-29 | 2019-01-28 | 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207024221A Division KR20200116110A (ko) | 2018-01-29 | 2019-01-28 | 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250025043A true KR20250025043A (ko) | 2025-02-20 |
Family
ID=67395723
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257004583A Pending KR20250025043A (ko) | 2018-01-29 | 2019-01-28 | 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법 |
| KR1020207024221A Ceased KR20200116110A (ko) | 2018-01-29 | 2019-01-28 | 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207024221A Ceased KR20200116110A (ko) | 2018-01-29 | 2019-01-28 | 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11337963B2 (https=) |
| EP (1) | EP3746058B1 (https=) |
| JP (2) | JP7758320B2 (https=) |
| KR (2) | KR20250025043A (https=) |
| CN (1) | CN111902137A (https=) |
| AU (1) | AU2019211458B2 (https=) |
| BR (1) | BR112020015068A2 (https=) |
| ES (1) | ES2948788T3 (https=) |
| IL (1) | IL276059B2 (https=) |
| MX (1) | MX2020007760A (https=) |
| MY (1) | MY209656A (https=) |
| RU (1) | RU2020125170A (https=) |
| SG (1) | SG11202007178VA (https=) |
| WO (1) | WO2019148087A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112024001927A2 (pt) | 2021-07-30 | 2024-04-30 | Evecxia Therapeutics Inc | Formas de dosagem gastrorretentivas de 5-hidroxitriptofano |
| US12409163B2 (en) * | 2021-07-30 | 2025-09-09 | Evecxia Therapeutics, Inc. | Method of enhancing 5-hydroxytryptophan (5-HTP) exposure |
| EP4392031A4 (en) | 2021-10-14 | 2025-07-30 | Evecxia Therapeutics Inc | METHOD FOR OPTIMIZING 5-HYDROXYTRYPTAMINE FUNCTION IN THE BRAIN FOR THERAPEUTIC PURPOSES |
| DE102022103658A1 (de) * | 2022-02-16 | 2023-08-17 | Joachim Kamprad | Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer |
| WO2024148354A1 (en) | 2023-01-06 | 2024-07-11 | Evecxia Therapeutics, Inc. | A method of enhancing 5-hydroxytryptophan (5-htp) exposure |
| CN119074695A (zh) * | 2024-08-29 | 2024-12-06 | 江南大学 | 一种可提高脑内5-ht水平的口服缓释制剂及其在改善失眠中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4658038A (en) | 1982-10-07 | 1987-04-14 | Research Foundation For Mental Hygiene, Inc. | N-acylated 5-hydroxytryptophan amide derivatives |
| FR2654931B1 (fr) | 1989-11-24 | 1993-08-27 | Trouillas Paul | Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa. |
| WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US20060013875A1 (en) | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US7101912B2 (en) | 2002-12-06 | 2006-09-05 | Xenoport, Inc. | Carbidopa prodrugs and derivatives, and compositions and uses thereof |
| US7585627B2 (en) * | 2004-05-21 | 2009-09-08 | Duke University | Polymorphism in tryptophan hydroxylase-2 controls brain serotonin synthesis |
| US20070213370A1 (en) * | 2005-11-18 | 2007-09-13 | H. Lundbeck A/S | 5-HTP Combination Therapy |
| WO2009043834A1 (en) | 2007-10-01 | 2009-04-09 | Neurosearch A/S | Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound |
| CN102202656A (zh) | 2008-08-15 | 2011-09-28 | 蒂宝制药公司 | 治疗和预防cns障碍的胃滞留药用组合物 |
| EP2531219A4 (en) * | 2010-02-05 | 2015-01-14 | Phosphagenics Ltd | Carrier composition |
| EP2629615B1 (en) | 2010-10-22 | 2018-10-10 | Duke University | Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies |
| CN103554005A (zh) | 2013-11-22 | 2014-02-05 | 长沙理工大学 | 一种左旋5-羟基色氨酸的简便合成新方法 |
-
2019
- 2019-01-28 MY MYPI2020003883A patent/MY209656A/en unknown
- 2019-01-28 US US15/733,423 patent/US11337963B2/en active Active
- 2019-01-28 RU RU2020125170A patent/RU2020125170A/ru unknown
- 2019-01-28 ES ES19743636T patent/ES2948788T3/es active Active
- 2019-01-28 KR KR1020257004583A patent/KR20250025043A/ko active Pending
- 2019-01-28 AU AU2019211458A patent/AU2019211458B2/en active Active
- 2019-01-28 EP EP19743636.3A patent/EP3746058B1/en active Active
- 2019-01-28 JP JP2020541352A patent/JP7758320B2/ja active Active
- 2019-01-28 BR BR112020015068-1A patent/BR112020015068A2/pt unknown
- 2019-01-28 IL IL276059A patent/IL276059B2/en unknown
- 2019-01-28 WO PCT/US2019/015391 patent/WO2019148087A1/en not_active Ceased
- 2019-01-28 KR KR1020207024221A patent/KR20200116110A/ko not_active Ceased
- 2019-01-28 MX MX2020007760A patent/MX2020007760A/es unknown
- 2019-01-28 CN CN201980021717.5A patent/CN111902137A/zh active Pending
- 2019-01-28 SG SG11202007178VA patent/SG11202007178VA/en unknown
-
2023
- 2023-07-21 JP JP2023119314A patent/JP2023153871A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL276059A (en) | 2020-08-31 |
| MY209656A (en) | 2025-07-29 |
| RU2020125170A (ru) | 2022-02-28 |
| JP2023153871A (ja) | 2023-10-18 |
| IL276059B1 (en) | 2024-04-01 |
| KR20200116110A (ko) | 2020-10-08 |
| JP2021511365A (ja) | 2021-05-06 |
| MX2020007760A (es) | 2020-10-28 |
| AU2019211458A1 (en) | 2020-08-06 |
| EP3746058A4 (en) | 2021-12-22 |
| US20210346345A1 (en) | 2021-11-11 |
| EP3746058B1 (en) | 2023-06-07 |
| AU2019211458B2 (en) | 2024-08-29 |
| CN111902137A (zh) | 2020-11-06 |
| WO2019148087A1 (en) | 2019-08-01 |
| US11337963B2 (en) | 2022-05-24 |
| SG11202007178VA (en) | 2020-08-28 |
| EP3746058C0 (en) | 2023-06-07 |
| JP7758320B2 (ja) | 2025-10-22 |
| IL276059B2 (en) | 2024-08-01 |
| BR112020015068A2 (pt) | 2021-01-05 |
| EP3746058A1 (en) | 2020-12-09 |
| ES2948788T3 (es) | 2023-09-19 |
| CA3089068A1 (en) | 2019-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019211458B2 (en) | Compositions and methods of enhancing 5-hydroxytryptophan bioavailability | |
| Kadriu et al. | Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments | |
| Cardinali et al. | Melatonin and its analogs in insomnia and depression | |
| US8969417B2 (en) | Pharmaceutical compositions for treatment of Parkinsons disease | |
| Zurowski et al. | Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism | |
| US20090203731A1 (en) | Treatment of depression and other affective disorders | |
| Poleszak et al. | A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice | |
| EP2145620A2 (en) | Gaboxadol for treating depression and other affective disorders | |
| EP3678664A1 (en) | Pridopidine for treating drug induced dyskinesias | |
| KR20060032598A (ko) | 세로토닌 재흡수 억제제 및 아고멜라틴의 조합 | |
| Celikyurt et al. | Serotonin noradrenaline reuptake inhibitors (SNRIs) | |
| CA3089068C (en) | Low-dose carbidopa for enhancing 5-hydroxytryptophan bioavailability | |
| Kaur et al. | Current management of obesity in an infertile female-recent advances and future prospective drugs | |
| KR20220106960A (ko) | 경구 제약 즉시 방출 조성물 및 체중 감량을 위한 치료 방법 | |
| WO2008035177A2 (en) | Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor | |
| de Biase et al. | ADMET considerations for restless leg syndrome drug treatments | |
| Ding et al. | Ketamine as a rapid-acting antidepressant: A scoping review of mechanisms and efficacy in treatment-resistant depression | |
| Simões | New advances in pharmacological treatment of depression | |
| CN1845730A (zh) | 5－羟色胺再摄取抑制剂与克塞平的组合 | |
| US20210275512A1 (en) | Pridopidine for treating drug induced dyskinesias | |
| Wilding | Pharmacological approaches for treating obesity | |
| Henter et al. | Novel therapeutic targets for bipolar disorder | |
| Moretti et al. | Memantine: Its Role in Vascular Dementia | |
| CA2692334A1 (en) | Gaboxadol for treating depression and other affective disorders | |
| Rogoz et al. | P. 2. b. 002 Risperidone, an atypical antipsychotic, enhances the effect of antidepressant drugs in animal models of depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20250212 Application number text: 1020207024221 Filing date: 20200821 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application |